Evidence map›Paper›PMID 33170840›Full record

ArticlePloS one2020

National-level effectiveness of ART to prevent early mother to child transmission of HIV in Namibia.

Andrew Agabu, Andrew L Baughman, Christa Fischer-Walker, Michael de Klerk, Nicholus Mutenda, Francina Rusberg, Dorothea Diergaardt, Ndumbu Pentikainen, Souleymane Sawadogo, Simon Agolory and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Andrew AgabuUS Centers for Disease Control and Prevention, Windhoek, Namibia.ORCID 0000-0002-3152-8102
Andrew L BaughmanUS Centers for Disease Control and Prevention, Windhoek, Namibia.
Christa Fischer-WalkerUS Centers for Disease Control and Prevention, Windhoek, Namibia.
Michael de KlerkUS Centers for Disease Control and Prevention, Windhoek, Namibia.
Nicholus MutendaNamibia Ministry of Health and Social Services, Windhoek, Namibia.
Francina RusbergNamibia Ministry of Health and Social Services, Windhoek, Namibia.
Dorothea DiergaardtNamibia Ministry of Health and Social Services, Windhoek, Namibia.
Ndumbu PentikainenNamibia Institute of Pathology, Windhoek, Namibia.
Souleymane SawadogoUS Centers for Disease Control and Prevention, Windhoek, Namibia.
Simon AgoloryUS Centers for Disease Control and Prevention, Windhoek, Namibia.
Thu-Ha DinhUS Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Ministry of Health and Social Services · NACenters for Disease Control and Prevention · USNamibia Institute of Pathology · NA

Funding

PEPFAR
6 · The paper itself

Abstract

backgroundNamibia introduced the prevention of mother to child HIV transmission (MTCT) program in 2002 and lifelong antiretroviral therapy (ART) for pregnant women (option B-plus) in 2013. We sought to quantify MTCT measured at 4-12 weeks post-delivery.

methodsDuring Aug 2014-Feb 2015, we recruited a nationally representative sample of 1040 pairs of mother and infant aged 4-12 weeks at routine immunizations in 60 public health clinics using two stage sampling approach. Of these, 864 HIV exposed infants had DNA-PCR HIV test results available. We defined an HIV exposed infant if born to an HIV-positive mother with documented status or diagnosed at enrollment using rapid HIV tests. Dried Blood Spots samples from HIV exposed infants were tested for HIV. Interview data and laboratory results were collected on smartphones and uploaded to a central database. We measured MTCT prevalence at 4-12 weeks post-delivery and evaluated associations between infant HIV infection and maternal and infant characteristics including maternal treatment and infant prophylaxis. All statistical analyses accounted for the survey design.

resultsBased on the 864 HIV exposed infants with test results available, nationally weighted early MTCT measured at 4-12 weeks post-delivery was 1.74% (95% confidence interval (CI): 1.00%-3.01%). Overall, 62% of mothers started ART pre-conception, 33.6% during pregnancy, 1.2% post-delivery and 3.2% never received ART. Mothers who started ART before pregnancy and during pregnancy had low MTCT prevalence, 0.78% (95% CI: 0.31%-1.96%) and 0.98% (95% CI: 0.33%-2.91%), respectively. MTCT rose to 4.13% (95% CI: 0.54%-25.68%) when the mother started ART after delivery and to 11.62% (95% CI: 4.07%-28.96%) when she never received ART. The lowest MTCT of 0.76% (95% CI: 0.36% - 1.61%) was achieved when mother received ART and ARV prophylaxis within 72hrs for infant and highest 22.32% (95%CI: 2.78% -74.25%) when neither mother nor infant received ARVs. After adjusting for mother's age, maternal ART (Prevalence Ratio (PR) = 0.10, 95% CI: 0.03-0.29) and infant ARV prophylaxis (PR = 0.32, 95% CI: 0.10-0.998) remained strong predictors of HIV transmission.

conclusionAs of 2015, Namibia achieved MTCT of 1.74%, measured at 4-12 weeks post-delivery. Women already on ART pre-conception had the lowest prevalence of MTCT emphasizing the importance of early HIV diagnosis and treatment initiation before pregnancy. Studies are needed to measure MTCT and maternal HIV seroconversion during breastfeeding.

Indexed as

AdolescentAdultAnti-HIV AgentsFemaleHIVHIV InfectionsHumansInfantInfant, NewbornInfectious Disease Transmission, VerticalMalePostpartum PeriodPregnancyPregnancy Complications, InfectiousYoung AdultAnti-HIV Agents

Identifiers

PMID33170840
PMCPMC7654758
OpenAlexW3105745174

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.